Letters
Trial of amiodarone for Ebola
Concerns about the off-licence use of amiodarone for Ebola
BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h272 (Published 20 January 2015) Cite this as: BMJ 2015;350:h272
- Ankur Gupta-Wright, academic clinical fellow in infectious diseases1,
- James Lavers, intensive care specialist registrar2,
- Sharon Irvine, clinical fellow (infectious diseases)3
- 1Department of Clinical Research, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
- 2Ysbyty Gwynedd, Bangor, UK
- 3Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
- ankurgw{at}outlook.com
We were disturbed by your article promoting the compassionate use of amiodarone for Ebola virus disease by the non-governmental organisation (NGO), Emergency, which suggested its use was endorsed by the Department for International Development and WHO.1 …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.